26 297

Cited 31 times in

Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model.

Authors
Choi, B; Hwang, Y; Kwon, HJ; Lee, ES; Park, Kc; Bang, D; Lee, S; Sohn, S
Citation
Journal of dermatological science, 52(2):87-97, 2008
Journal Title
Journal of dermatological science
ISSN
0923-18111873-569X
Abstract
BACKGROUND: Anti-TNFalpha antibodies have been used for treating inflammation in patients. But, more effective and safer drugs need to be developed for improved future therapeutic use. OBJECTIVES: To inhibit the expression of TNFalpha, we used small interfering RNAs (siRNAs) to reduce over expression of TNFalpha in vitro in cell cultures and in an in vivo Behcet's disease-like (BD) mouse model for amelioration of chronic inflammation. METHODS: TNFalpha siRNA was injected intraperitoneally twice with a 1-week interval. To compare the efficacy of TNFalpha siRNA versus an anti-TNFalpha antibody, Infliximab and Etanercept were administered to symptomatic mice with inflamed tissue. RESULTS: Intraperitoneal delivery of TNFalpha siRNA effectively decreased BD symptoms in 18 of 32 cases (56.3%). Scrambled siRNA treatment decreased BD symptoms in 2 of 19 cases (10.5%). Infliximab was effective in 11 of 27 cases (40.7%) and Etanercept was also effective in 9 of 25 cases (36.0%) at the end of the second week after treatment. TNFalpha siRNA reduced serum levels of TNFalpha (1.57 +/- 0.43pg/ml), compared to levels in mice not injected (84.02 +/- 24.59pg/ml) (p<0.01) or scramble injected (118.89 +/- 20.08pg/ml) (p<0.01). After single injection of TNFalpha siRNA, improvement of BD symptoms showed at 9 +/- 7th day on an average, contrary, in Infliximab injected group, improvement was apparent at 15 +/- 4th day after injection (p<0.05). CONCLUSION: We show that siRNAs can be employed to inhibit cytokine gene expression in an in vivo disease mouse model. This inhibition may, therefore, be attributed to the improvement of inflammatory symptoms.
MeSH terms
AnimalsAnti-Inflammatory Agents/pharmacologyAnti-Inflammatory Agents/therapeutic useAntibodies, Monoclonal/pharmacologyAntibodies, Monoclonal/therapeutic useBehcet Syndrome/drug therapy*Behcet Syndrome/metabolismBehcet Syndrome/virology*Cells, CulturedCytokines/metabolismDisease Models, AnimalImmunoglobulin G/pharmacologyImmunoglobulin G/therapeutic useLipopolysaccharides/metabolismMacrophages/drug effectsMacrophages/metabolismMaleMiceMice, Inbred ICRRNA, Small Interfering/pharmacologyRNA, Small Interfering/therapeutic use*Receptors, Tumor Necrosis Factor/therapeutic useSimplexvirus/pathogenicity*Treatment OutcomeTumor Necrosis Factor-alpha/antagonists & inhibitorsTumor Necrosis Factor-alpha/genetics*Tumor Necrosis Factor-alpha/metabolism
DOI
10.1016/j.jdermsci.2008.05.001
PMID
18585901
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Dermatology
Journal Papers > School of Medicine / Graduate School of Medicine > Microbiology
AJOU Authors
이은소손성향
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse